Multi-omics gene panel for prostate cancer detection and prognosis
A multi-omics gene panel integrating somatic mutations and gene expression data addresses the challenge of distinguishing prostate cancer forms in diverse populations, enhancing early detection and prognosis through personalized treatment strategies.
Patent Information
- Application Number
- PCT/IN2026/050766
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-05
- Filing Date
- 2026-05-04
- Publication Date
- 2026-11-12
AI Technical Summary
Current diagnostic tools for prostate cancer, such as PSA testing and tissue biopsies, struggle to accurately distinguish between indolent and aggressive forms of the disease, particularly in diverse populations like the Indian demographic, leading to incorrect diagnoses and inadequate treatment plans.
A multi-omics gene panel integrating somatic mutation profiles, copy number alterations, and differential gene expression data from Indian prostate cancer patients, utilizing synthetic oligonucleotides, primers, and hybridization probes to detect specific genes like KMT2C, BRCA2, and GRIN1, for early detection and prognosis.
The panel provides precise molecular characterization and risk stratification, enabling early detection and personalized treatment decisions, reducing unnecessary interventions for low-risk cancers while ensuring timely management of high-risk cases.
Smart Images

Figure IN2026050766_12112026_PF_FP_ABST
Abstract
Description
[0001] MULTI-OMICS GENE PANEL FOR PROSTATE CANCER DETECTION AND PROGNOSIS
[0002] EARLIEST PRIORITY DATE:
[0003] This Application claims priority from a Provisional patent application filed in India having Patent Application No. 202511043306, filed on 05th May 2025 and titled “MULTI-OMICS GENE PANEL FOR PROSTATE CANCER DETECTION AND PROGNOSIS”.
[0004] FIELD OF INVENTION
[0005] Embodiment of the present invention relates to multi-omics gene panel for prostate cancer detection and prognosis. More particularly, the present invention relates to a multi-omics gene panel comprising synthetic oligonucleotides, primers, and hybridization probes designed to detect somatic mutations, copy number alterations, and differential gene expression patterns specific to prostate cancer.
[0006] BACKGROUND
[0007] Prostate cancer is a significant health concern worldwide, with increasing incidence rates in many countries. This malignancy develops in the prostate gland and may progress from localized disease to metastatic stages if left undetected or untreated. Early detection and accurate risk stratification are crucial for improving patient outcomes and guiding appropriate treatment decisions.
[0008] According to GLOBOCAN 2020 estimates, Prostate Cancer (PCa) is the second most leading cause of cancer incidence, and the fifth leading cause of cancer-associated death among men worldwide. In India, PCa has the third highest incidence rate among males, and it has been alarmingly increased by -30% from the year 1990 to 2016.Unlike the West, the majority of PCa patients (-85%) in India present with advanced-stage disease at the time of first diagnosis, while in the United States, it is only -15%. A key challenge in clinical management lies in the inability of current diagnostic tools (e.g. PSA testing, DRE, and conventional histopathology) to reliably differentiate between indolent and aggressive PCa, especially at early stages. These limitations frequently often led to incorrect diagnosis, poor prognosis, and inadequate treatment. Hence, a major unmet need is the early-stage diagnostic and prognostic tools that can distinguish between benign, indolent, and aggressive forms of the disease. Prostate cancer is a genetically heterogeneous disease, causally associated with various types of genetic aberrations, including structural variants, somatic mutations, and copy-number alterations. Based on the molecular and genetic signatures, PCa has been classified into distinct subtypes, defined by gene fusions involving ETS transcription family, such as TMPRSS-ERG, RAF kinase rearrangements, SPINK1 overexpression, mutations in the SPOP, FOXA1, IDH1, and biallelic loss of CDK12. Thus, categorizing PCa patients based on genetic alterations would be instrumental in defining molecular subtypes and associated therapeutic strategies. This molecular heterogeneity often complicates risk assessment and treatment planning, particularly when comprehensive profiling of PCa patients from India and their utility in the clinic is completely unknown.
[0009] Current diagnostic methods for prostate cancer rely primarily on prostate-specific antigen (PSA) testing, digital rectal examination (DRE), and tissue biopsy. However, these approaches have limitations in terms of sensitivity, specificity, and ability to distinguish between indolent and aggressive forms of the disease. PSA testing, while widely used, can lead to overdiagnosis and overtreatment of low-risk cancers. Conversely, some aggressive cancers may be missed or underestimated by conventional diagnostic tools.
[0010] The heterogeneous nature of prostate cancer presents challenges in accurately assessing disease progression and prognosis. Tumors can exhibit varying degrees of aggressiveness, even within the same patient, making it difficult to determine theappropriate course of treatment based solely on traditional clinical and pathological parameters.
[0011] Recent advances in genomic and molecular profiling technologies have opened new avenues for understanding the underlying biology of prostate cancer. Multi-omics approaches, which integrate data from various molecular levels such as genomics, transcriptomics, and proteomics, offer the potential to provide a more comprehensive characterization of tumor biology and identify novel biomarkers for diagnosis and prognosis.
[0012] Gene panels, consisting of multiple genetic markers, have shown promise in improving the accuracy of cancer detection and risk stratification. These panels can potentially capture the molecular heterogeneity of prostate cancer and provide additional information beyond traditional clinical factors. However, the development of gene panels that are both sensitive and specific for prostate cancer, particularly in diverse populations, remains an ongoing area of research.
[0013] Additionally, there is growing interest in developing minimally invasive diagnostic methods, such as liquid biopsies, which could potentially detect prostate cancer through analysis of circulating tumor cells or cell-free DNA in blood or urine samples. These approaches aim to reduce the need for invasive tissue biopsies and provide a means for longitudinal monitoring of disease progression.
[0014] As the field of molecular diagnostics continues to evolve, there is a need for improved tools that can accurately detect prostate cancer at early stages, distinguish between indolent and aggressive disease, and guide personalized treatment decisions. Such advancements could potentially reduce unnecessary interventions for low-risk cancers while ensuring timely and appropriate management of high-risk cases.
[0015] Several genomic classifiers are currently available in the art. For example, US8440407B2 discloses a method for predicting prostate cancer recurrence based on agene expression signature. While effective for its intended purpose, this panel relies solely on transcriptomic (mRNA) data derived from western patient cohorts. It does not account for somatic DNA mutations or copy number alterations (CNAs), which are critical drivers of tumor stability. Furthermore, as gene expression profiles can vary significantly between ethnic groups due to epigenetic and environmental factors, the predictive accuracy of such western- derived panels when applied to the Indian population — where the disease presentation is often more aggressive at diagnosis — remains uncertain.
[0016] Similarly, US7718369B2 describes methods for detecting prostate cancer by identifying gene fusions, specifically the TMPRSS2-ERG fusion, which is a predominant molecular subtype in Caucasian populations (found in -50% of cases). However, subsequent genomic studies have demonstrated that the frequency of TMPRSS2-ERG fusions is significantly lower in Asian and Indian populations (often <20%). Consequently, diagnostic tests centered on this specific fusion event suffer from reduced sensitivity in the Indian demographic, leading to a high rate of false negatives.
[0017] Furthermore, US20140073535A1 describes urine-based markers such as DLX1 and HOXC6 for detecting high-grade prostate cancer. While this represents a non-invasive approach, the panel is limited to a small set of expression markers and does not interrogate "Early Driver" events that occur in pre-malignant lesions, such as Prostatic Intraepithelial Neoplasia (PIN). The inability to detect these early molecular shifts limits the utility of such panels for active surveillance of asymptomatic or early-stage patients, which is a primary need in developing nations where late-stage diagnosis is common.
[0018] Therefore, there remains a long-felt need in the art for a comprehensive, populationspecific, multi-omics gene panel that may accurately diagnose prostate cancer in the Indian population despite the genetic differences from western cohorts, integratemutation, copy number, and expression data for superior risk stratification, and enable non-invasive monitoring through liquid biopsy platforms to facilitate early detection. Therefore, there is a need to provide a novel multi-omics gene panel and associated methods for the detection and prognosis of prostate cancer.
[0019] SUMMARY
[0020] This summary is provided to introduce a selection of concepts in a simplified form that are further described below in the detailed description. This summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used as an aid in determining the scope of the claimed subject matter.
[0021] According to an aspect of the present disclosure, a multi-omics generated gene panel for prostate cancer early detection, diagnosis, and prognosis is provided. The gene panel includes a set of genes identified through integrative analysis of somatic mutation profiles, copy number alterations, and differential gene expression data derived from fresh tumor tissue and benign prostatic hyperplasia specimens from Indian patients. The gene panel is configured to detect prostate cancer using tissue and minimally invasive specimens.
[0022] In an embodiment of the present invention, a multi-omics nucleic acid probe panel is provided. The multi-omics nucleic acid probe panel comprises a combination of one of synthetic oligonucleotides, primers, and hybridization probes designed to hybridize to one of genomic DNA sequences and complementary DNA (cDNA) sequences corresponding to the following genes: (a) KMT2C, BRCA2, ATRX, ZFHX3, FAT3, FOXA1, LRP1B, NRG1, and CDK12,' (b) GRIN1, GMEB2, ATM, PTEN, FANCA, CYC1, and CI)HR2, (c) HDAC9, MMP1, FGFR3, SLC4A4, DNAH8, and SLC45A3' and (d) CIP2A, FAM83A, CD200, LETR1, CAMK2N1, DSPP, DMP1, SPAG6, BAHCC1, and CHRM2.In another embodiment of the present invention, a kit for a molecular profiling and risk stratification of prostate cancer is provided. The kit comprises (a) the multi-omics nucleic acid probe panel as explained earlier in one of the embodiments of the present invention; (b) reagents suitable for nucleic acid extraction from a biological sample; (c) reagents for at least one of nucleic acid amplification and hybridization; and (d) at least one of a detectable label and a marker.
[0023] Accordingly, the present invention provides a unified, multi-layered diagnostic platform that enables precise molecular characterization of prostate tumors, molecular classification, and risk assessment across diverse clinical settings.
[0024] To further clarify the advantages and features of the present invention, a more particular description of the invention will follow by reference to specific embodiments thereof, which are illustrated in the appended figures. It is to be appreciated that these figures depict only typical embodiments of the invention and are therefore not to be considered limiting in scope. The invention will be described and explained with additional specificity and detail with the appended figures.
[0025] BRIEF DESCRIPTION OF THE DRAWINGS
[0026] The disclosure will be described and explained with additional specificity and detail with the accompanying figures in which:
[0027] FIG. 1A illustrates an oncoplot of top genes exclusively mutated in prostate cancer patients (N=89) from India, in accordance with an embodiment of the present disclosure;
[0028] FIG. IB illustrates a heatmap of genes mutated and upregulated (compared to BPH) in PCa specimens from India, in accordance with an embodiment of the present disclosure;FIG. 2A illustrates an oncolpot of putative early diagnostic driver genes mutated in PIN and PCa specimens, in accordance with an embodiment of the present disclosure;
[0029] FIG. 2B illustrates a forest plot of mutational frequencies in PCa Vs PIN groups, in accordance with an embodiment of the present disclosure;
[0030] FIG. 3A illustrates an oncoplot representing the most altered (SNVs and CNAs) candidates in PCa patients from India, in accordance with an embodiment of the present disclosure;
[0031] FIG. 3B illustrates a heatmap of genes amplified and upregulated (compared to BPH) in PCa specimens from India, in accordance with an embodiment of the present disclosure; and
[0032] FIG. 4 illustrates a heatmap of differentially expressed genes in high grade Vs low grade PCa specimens from India, in accordance with an embodiment of the present disclosure.
[0033] Further, those skilled in the art will appreciate that elements in the figures are illustrated for simplicity and may not have necessarily been drawn to scale. Furthermore, in terms of the construction of the device, one or more components of the device may have been represented in the figures by conventional symbols, and the figures may show only those specific details that are pertinent to understanding the embodiments of the present disclosure so as not to obscure the figures with details that will be readily apparent to those skilled in the art having the benefit of the description herein.
[0034] DETAILED DESCRIPTION
[0035] For the purpose of promoting an understanding of the principles of the disclosure, reference will now be made to the embodiment illustrated in the figures and specific language will be used to describe them. It will nevertheless be understood that nolimitation of the scope of the disclosure is thereby intended. Such alterations and further modifications in the illustrated system, and such further applications of the principles of the disclosure as would normally occur to those skilled in the art are to be construed as being within the scope of the present disclosure.
[0036] The terms "comprises", "comprising", or any other variations thereof, are intended to cover a non-exclusive inclusion, such that a process or method that comprises a list of steps does not include only those steps but may include other steps not expressly listed or inherent to such a process or method. Similarly, one or more components, compounds, and ingredients preceded by "comprises... a" does not, without more constraints, preclude the existence of other components or compounds or ingredients or additional components. Appearances of the phrase "in an embodiment", "in another embodiment" and similar language throughout this specification may, but not necessarily do, all refer to the same embodiment.
[0037] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terms "gene panel," "multi-omics panel," and "molecular profile" refer to a distinct set of genetic markers (genes) selected for their ability to diagnose, prognose, or classify prostate cancer based on somatic mutations, copy number alterations (CNAs), and / or differential gene expression.
[0038] The term "somatic mutation" refers to a genetic alteration acquired by a cell that can be passed to the progeny of the mutated cell in the course of cell division but is not inherited. The term "copy number alteration" or "CNA" refers to somatic changes to chromosome structure that result in gain or loss in copies of sections of DNA. The term "differential expression" refers to a statistically significant difference in the level of a transcript (RNA) or protein between two experimental conditions (e.g., tumor vs. benign tissue).The term "primer" or "probe" refers to a synthetic oligonucleotide, whether occurring naturally as in a purified restriction digest or produced synthetically, which is capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product, which is complementary to a nucleic acid strand, is induced.
[0039] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this disclosure belongs. The system, methods, and examples provided herein are only illustrative and not intended to be limiting.
[0040] The present disclosure relates to a multi-omics gene panel for prostate cancer detection and prognosis. This multi-omics gene panel comprises a set of genes identified through a comprehensive multi-omics integrative analysis, including somatic mutation profiles, copy number alterations (CNA), and differential gene expression data derived from fresh tumor tissue and benign prostatic hyperplasia (BPH) specimens from India. The multi-omics gene panels address critical clinical needs for improved risk stratification and treatment selection in prostate cancer management.
[0041] Referring now to the drawings, and more particularly to FIG. 1 through FIG.4, where similar reference characters denote corresponding features consistently throughout the figures, there are shown preferred embodiments and these embodiments are described in the context of the following exemplary system and / or method.
[0042] FIG. 1A refers to an oncolpot of top genes exclusively mutated in prostate cancer patients (N=89) from India wherein, the upper plot shows the tumor mutation burden for each sample. The frequency of samples mutated showed on the right side. Each column represents a sample, and it is grouped according to their Gleason score (bottom). Each row represents a particular gene with different variant classification (annotated at bottom). This list of mutated genes represents the putative diagnosticgenes for prostate cancer. The list is curated upon removing the commonly mutated genes between cancer and benign group.
[0043] FIG. IB refer to a heatmap of genes mutated and upregulated (compared to BPH) in PCa specimens from India, wherein, the heatmap of RNA-Seq expression z-scores computed for genes that are significantly upregulated (Benjamini -Hochberg adjusted p-value < 0.05) as well as mutated in PCa specimens. The genes (rows) are clustered using hierarchical clustering using the Euclidean linkage method. Samples are annotated based on the type of tissue and the color code shows the z-score, with a red color indicating higher expression of a gene and blue color indicating lower expression of a gene.
[0044] FIG. 2A refer to an onncolpot of putative early diagnostic driver genes mutated in PIN and PCa specimens wherein, the frequency of samples mutated showed on the right side. Each column represents a sample, and it is grouped according to their Gleason score (bottom). Each row represents a particular gene with different variant classification (annotated at bottom). All these genes are found to be mutate din the PIN as well as the PCa group indicating putative early driver events.
[0045] FIG. 2B refer to a forest plot of mutational frequencies in PCa Vs PIN groups wherein, the dots represent the point estimate of the odds ratio (OR) which is an indicative of how much more (or less) frequent a mutation in that gene is in PCa Vs PIN (OR < 1: more frequent in PCa than PIN; OR > 1 : more frequent in PIN than PCa). Horizontal line represents the 95% confidence interval for the odds ratio. All these genes are present in PIN and retained in PCa which is an indication of putative early driver mutations, could be of great early diagnostic candidates.
[0046] FIG. 3 A refer to an oncoplot representing the most altered (SNVs and CNAs) candidates in PCa patients from India wherein, the frequency of samples altered showed on the right side. Each column represents a sample, and it is grouped according to the Gleason score (bottom). Each row represents a particular gene with differentvariant classification (annotated at bottom). The most frequently altered genes were found to be GRIN1 and GMEB2. We found exclusive amplification events in these two genes, while GRIN1 also exhibit a complex event (amplification and in frame deletion in a same specimen).
[0047] FIG. 3B refer to a heatmap of genes amplified and upregulated (compared to BPH) in PCa specimens from India wherein, the heatmap corelates the copy number amplification data with gene expression data further indicating the role of these genes as putative diagnostic and prognostic markers for prostate cancer.
[0048] FIG. 4 refer to a heatmap of differentially expressed genes in high grade Vs low grade PCa specimens from India. The heatmap displays Z-score normalized expression values of significantly upregulated and downregulated genes (adjusted p < 0.05, |log2FC| > 0.7) between high-grade and low-grade PCa samples. Only genes with valid gene symbol annotations were included. Upregulated genes in high-grade PCa such as CIP2A, FAM83A, CD200, and LETR1 are associated with tumor aggressiveness and poor prognosis. Downregulated genes including EGR3 an 1ST 1 suggest loss of tumorsuppressive functions. The genes (rows) are clustered using hierarchical clustering using the Euclidean linkage method. Samples are annotated based on the grade of cancer and the color code shows the z-score, with a red color indicating higher expression and blue color indicating lower expression.
[0049] Embodiments of the present invention provides a novel, multi-omics gene panel tailored for the detection, early diagnosis, and prognostic risk stratification of prostate cancer (PCa). Existing genomic panels for prostate cancer are largely derived from Western populations (e.g., TCGA, SU2C datasets). The present invention has identified the genomic landscape of prostate cancer in certain demographic populations, specifically the Indian cohort, exhibits distinct molecular signatures that are not adequately captured by existing commercial panels.Accordingly, embodiments of the present invention provide a consolidated panel of biomarkers identified through a rigorous integrative analysis of Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS) of fresh tumor tissues, Benign Prostatic Hyperplasia (BPH) specimens, and Prostatic Intraepithelial Neoplasia (PIN) lesions. This panel uniquely integrates three layers of genomic data: somatic mutation profiles, somatic copy number alterations (CNAs), and differential gene expression signatures, to provide a comprehensive tool for clinical decisionmaking.
[0050] In an embodiment of the present invention, a multi-omics nucleic acid probe panel is provided. The multi-omics nucleic acid probe panel comprises a combination of one of synthetic oligonucleotides, primers, and hybridization probes designed to hybridize to one of genomic DNA sequences and complementary DNA (cDNA) sequences corresponding to the following genes: (a) KMT2C, BRCA2, ATRX, ZFHX3, FAT3, FOXA1, LRP1B, NRG1, and CDK12,' (b) GRIN1, GMEB2, ATM, PTEN, FANCA, CYC1, and CI)HR2, (c) HDAC9, MMP1, FGFR3, SLC4A4, DNAH8, and SLC45A3' and (d) CIP2A, FAM83A, CD200, LETR1, CAMK2N1, DSPP, DMP1, SPAG6, BAHCC1, and CHRM2. The combination of at least one of synthetic oligonucleotides, primers, and hybridization probes are configured to detect at least one of somatic non-silent mutations, genomic copy number alterations, and differential transcript expression levels. The multi-omics nucleic acid probe panel further comprises a subset of at least one of the synthetic oligonucleotides, primers, and hybridization probes configured to detect early-stage driver mutations in RBMX, DMBT1, CHD6, and ZFHX4. At least one of synthetic oligonucleotides, primers, and hybridization probes corresponding to KMT2C, BRCA2, ATRX, and ZFHX3 are designed to hybridize to exonic regions associated with non-silent somatic mutations.
[0051] In an exemplary embodiment of the present invention, at least one of the synthetic oligonucleotides, primers, and hybridization probes corresponding to GRIN1, GMEB2, CYC1, and CDHR2 are configured to quantify genomic amplification events. At leastone of the synthetic oligonucleotides, primers, and hybridization probes corresponding to PTEN, ATM, and FANCA are configured to quantify genomic deletion events. At least one of the synthetic oligonucleotides, primers, and hybridization probes corresponding to CIP2A, FAM83A, CD200, LETR1, CAMK2N1, BAHCC1, and CHRM2 are configured to quantify transcript abundance through reverse transcription and amplification. The multi-omics nucleic acid probe panel further comprising at least one of synthetic oligonucleotides, primers, and hybridization probes specific for at least one reference gene selected from ERG, IDH1, SPOP, MYC, AR, RBI, and CHD1. The synthetic oligonucleotides have a length between 15 and 30 nucleotides and a melting temperature (Tm) between 55 °C and 65 °C. The hybridization probes comprise fluorescent labels selected from at least one of FAM, VIC, NED, ROX, Cy3, Cy5, and Texas Red.
[0052] In another embodiment of the present invention, a kit for a molecular profiling and risk stratification of prostate cancer is provided. The kit comprises (a) the multi-omics nucleic acid probe panel as explained earlier in one of the embodiments of the present invention; (b) reagents suitable for nucleic acid extraction from a biological sample; (c) reagents for at least one of nucleic acid amplification and hybridization; and (d) at least one of a detectable label and a marker. The kit further comprises positive control nucleic acid samples and negative control nucleic acid samples, a set of instructions detailing extraction protocols, amplification conditions, and interpretation guidelines, reagents packaged in separate vessels optimized for storage at temperatures between -20 °C and 25 °C.
[0053] In an exemplary embodiment of the present invention, the reagents suitable for nucleic acid extraction is selected from a group comprising of silica-based spin columns, magnetic beads, chaotropic salts, and Proteinase K configured for an isolation of one of DNA and RNA from one of fresh tissue and formalin-fixed paraffin- embedded (FFPE) tissue. The reagents for at least one of nucleic acid amplification and hybridization are selected from the group comprising of a thermostable DNApolymerase, a reverse transcriptase, deoxynucleotide triphosphates (dNTPs), buffer solutions, and ligases configured for one of multiplex PCR and next-generation sequencing (NGS) library preparation. At least one of the detectable label and the marker is selected from the group comprising of a fluorophore, a biotinyl moiety, a chemiluminescent agent, an enzymatic conjugate, and a radioisotope. The biological sample is selected from at least one of fresh tissue, formalin-fixed paraffin- embedded (FFPE) tissue, blood, plasma, serum, urine, circulating tumor cells (CTCs), and cell-free DNA (cfDNA). The kit is configured to use with at least one of a next-generation sequencing (NGS) platform, a quantitative polymerase chain reaction (qPCR) platform, and a digital droplet PCR (ddPCR) platform. The kit comprises reagents packaged in separate vessels optimized for storage at temperatures between -20 °C and 25 °C.
[0054] In another embodiment of the present invention, a collection of isolated synthetic oligonucleotide primers is provided. The collection of isolated synthetic oligonucleotide primers comprises (a) forward and reverse primers specific for amplification of exonic regions of KMT2C, BRCA2, ATRX, and ZFHX3 that harbor non-silent somatic mutations; (b) forward and reverse primers specific for amplification of genomic regions of GRINI, GMEB2, PTEN, FANCA, and ATM for copy number determination; and (c) forward and reverse primers specific for amplification of cDNA sequences of CIP2A, FAM83A, CD200, LETR1, CAMK2N1, BAHCC1, and CHRM2 for transcript quantification. Each primer is between 18 and 25 nucleotides in length and said primers are optimized for annealing temperatures between 58 °C and 62 °C for multiplex amplification reactions.
[0055] In another embodiment of the present invention, a collection of antibodies specific for protein products encoded by genes is provided. The collection of antibodies specific for protein products encoded by genes selected from KMT2C, BRCA2, ATRX, ZFHX3, HDAC9, MMP1, FGFR3, CIP2A, FAM83A, CD200, and LETR1. Said antibodies are conjugated to a detectable label selected from one of horseradish peroxidase (HRP), alkaline phosphatase (AP), and a fluorescent dye. Further, said antibodies aremonoclonal antibodies produced by hybridoma cell lines. Also, said antibodies are configured for immunohistochemical staining of formalin-fixed paraffin-embedded (FFPE) tissue sections.
[0056] In another embodiment of the present invention, a reagent composition is provided. The reagent composition comprising (a) the multi-omics nucleic acid probe panel as explained earlier in one of the embodiments of the present invention; (b) a master mix containing thermostable DNA polymerase, dNTPs, and MgCE optimized for multiplex amplification; (c) reverse transcriptase enzyme for cDNA synthesis from RNA templates; and (d) at least one of fluorescent intercalating dyes and TaqMan probes for real-time detection.
[0057] In an exemplary embodiment of the present disclosure, a whole exome sequencing (WES) and a whole transcriptome sequencing (WTS) of fresh prostate tissue specimens are performed to elucidate the molecular heterogeneity of prostate cancer (PCa) specific to Indian patients. The tissue specimens include treatment-naive prostate cancer samples, benign prostatic hyperplasia (BPH) samples, and prostatic intraepithelial neoplasia (PIN) lesion specimens.
[0058] In an exemplary embodiment of the present disclosure, the gene panels are developed using a rigorous, a multi-layered analytical approach that incorporates three primary data types.
[0059] Firstly, somatic mutations are identified by processing and analyzing WES data through standard bioinformatics pipelines. The resulting mutations are filtered to retain only non-silent mutations — i.e., those that result in alterations to the amino acid sequence of a protein — and are further screened for functional relevance.
[0060] Secondly, somatic copy number alterations (CNAs) are determined by analyzing processed BAM files derived from the WES data. This analysis enables the identification of genome-wide regions exhibiting somatic copy number alterations,including significant gains / amplifications and deletions that are associated with prostate cancer. Both focal alterations and broad chromosomal events are considered to ensure comprehensive genomic profiling.
[0061] Thirdly, gene expression profiles are obtained by processing and analyzing WTS data to identify differentially expressed genes (DEGs) in prostate cancer specimens in comparison to benign tissue specimens. The resulting expression data are further correlated with the identified somatic mutations and CNAs to determine genes that demonstrate multi-layered evidence of functional involvement in the molecular pathology of prostate cancer.
[0062] Development of diagnostic gene panel:
[0063] In an exemplary embodiment of the present disclosure, common genes found to be mutated in both benign prostatic hyperplasia (BPH) and prostate cancer (PCa) specimens are excluded, thereby generating an exclusive gene set comprising recurrently mutated genes specific to PCa specimens. This curated gene panel (FIG 1A) is indicative of its potential utility as a diagnostic biomarker for distinguishing malignant conditions from benign prostatic hyperplasia. Among the identified genes, TP53 exhibits the highest mutation frequency (24%), reaffirming its established role as a tumor suppressor frequently inactivated across various cancer types. Additionally, genes such as SYNE1 and CSMD3, mutated in 17% and 16% of PCa cases respectively, are implicated in nuclear envelope integrity and tumor suppression, thereby suggesting their involvement in genomic instability and disease progression.
[0064] In a further embodiment, the identified gene set is curated to assess the functional relevance of the most frequently mutated genes in the context of prostate cancer. Several novel mutations, specific to the studied cohort, are observed, reflecting the distinct genomic landscape of the Indian population. Notably, CDK12 a key modulator of DNA damage response and transcriptional elongation is found mutated in 3% of PCa cases, in line with its emerging role in aggressive PCa subtypes. The absence of thesemutations in BPH specimens further underscores their specificity to malignant transformation, thereby enhancing their suitability as candidate diagnostic markers for accurate detection of prostate cancer.
[0065] In yet another embodiment, an integrative analysis incorporating somatic mutation data and gene expression profiles is performed, resulting in the identification of a distinct subset of genes that are both exclusively mutated and significantly upregulated in PCa specimens (FIG IB). This dual-layered genomic alteration enhances the specificity and robustness of the identified genes as putative diagnostic markers for prostate malignancy. For example, HDAC9 (involved in chromatin remodeling and transcriptional silencing), MMP1 (facilitator of osteogenic differentiation via JNK and ERK pathways), FGFR3 (a tyrosine kinase receptor involved in proliferative signaling), SLC4A4 (implicated in pH regulation and metabolism), and DNAH8 (enhancer of androgen receptor activity in PCa) are among the most upregulated in PCa specimens. Furthermore, SLC45A3, an androgen-responsive gene, is observed to be both mutated and upregulated in the present cohort. The exclusive presence and concordant upregulation of these genes in PCa specimens establishes their candidacy as robust molecular markers for the diagnosis of prostatic malignancy.
[0066] Putative early diagnostic genes
[0067] In an exemplary embodiment of the present disclosure, given that a substantial proportion of prostate cancer (PCa) patients, approximately 85% are diagnosed at advanced stages of the disease, early detection is of critical clinical importance. To identify putative early diagnostic driver genes in prostate tumorigenesis, a comparative analysis is performed between the mutation profiles of prostatic intraepithelial neoplasia (PIN) specimens (N=2) — a non-malignant proliferation of prostatic epithelial cells lining the ducts and acini — and prostate cancer specimens (N=89). Through this analysis, a subset of genes that are commonly mutated in both PIN and PCa specimens are curated (FIG 2A). The presence of these shared mutations across pre-malignantand malignant stages indicates their potential role as early molecular events in prostate cancer development.
[0068] In a further embodiment, specific genes identified in both PIN and PCa specimens exhibit mutation frequencies suggestive of their significance as early diagnostic markers. For example, RBMX (mutation frequency: 10%) is implicated in telomere stability maintenance, DMBT1 (8%) is associated with immune defense mechanisms, CHD6 (7%) plays a role in chromatin remodeling and transcriptional activation in PCa, and ZFHX4 (7%) is involved in chromatin remodeling and transcriptional regulation. These genes are not only present in the earliest detectable stage of prostatic lesion development but also demonstrate sustained alteration in full-blown malignancy, highlighting their potential utility as early diagnostic biomarkers.
[0069] Furthermore, a comparative frequency analysis between PIN and PCa groups (FIG 2B) reveals that the mutations observed in PIN specimens persist at high frequencies within the PCa cohort. This continuity supports the hypothesis that these genetic alterations constitute early driver events that may contribute to the initiation of malignant transformation. Accordingly, mutations are selectively included in the diagnostic gene panel based on their novelty and predicted deleterious impact, thereby reinforcing the clinical utility of these genes as early molecular indicators for the detection and risk stratification of prostate cancer.
[0070] In a further embodiment of the present disclosure, significant somatic copy number alterations (CNAs) are identified in prostate cancer (PCa) specimens, including recurrent deletions in major PCa driver genes such as PTEN (-39%), TP 53 (38%), FANCA (35%), and ATM (34%), along with several other prostate cancer-associated genes. In addition, copy number gains or amplifications are observed in GRIN1 (49%), a component of the NMDA receptor complex implicated in calcium signaling and cellular plasticity, and GMEB2 (47%), a glucocorticoid modulatory element-binding protein. These genes represent the most frequently altered loci within the cohortanalyzed (FIG 3A), with alteration frequencies notably higher than those reported in the TCGA and SU2C datasets.
[0071] In yet another embodiment, transcriptomic analysis confirms a correlation between genomic amplification and elevated expression of GRIN1 and GMEB2 (FIG 3B).
[0072] Amplification events involving these genes are observed predominantly in high-grade PCa specimens, suggesting their potential role in disease progression and aggressiveness. Furthermore, other genes such as CYC1, GLI4, FGFR3, and CCNF also exhibit concurrent amplification and overexpression, supporting their involvement in tumor progression and enhanced proliferative signaling pathways. The co-occurrence of amplification and upregulation reinforces the relevance of these genes as molecular indicators of advanced disease states in prostate cancer.
[0073] In accordance with the above, the integration of mutation profiles, copy number alterations, and gene expression data facilitates the identification of a comprehensive panel of putative diagnostic genes. This panel is expected to aid in early detection, differential diagnosis, risk stratification, and the identification of therapeutic targets in prostate cancer. The consolidated list of these candidate genes is provided in Table 1 as part of the diagnostic gene panel proposed in the present disclosure.
[0074] Table 1: Diagnostic Gene Panel
[0075] Genes Alteration Alteration Alteration Alteration S.N.
[0076] name type details (DNA details level) (Protein level)
[0077] 1 KMT2C Mutation Frame Shift D c.8617del p.Cys2873V el alfsTer33 2 KMT2C Mutation Missense_Mut c.2681G>A p.Arg894Gln ation
[0078]
[0079] KMT2C Mutation Missense_Mut c.1042G>A p.Asp348As ation n KMT2C Mutation Missense_Mut c.943G>A p.Gly315Ser ation
[0080] KMT2C Mutation Missense_Mut c.13756T>C p.Tyr4586Hi ation s KMT2C Mutation Frame Shift D c.5929del p.Glnl977As el nfsTerl3 KMT2C Mutation Missense_Mut c.5053G>T p.Alal685Se ation r KMT2C Mutation Nonsense_Mut C.1173OA p.Cys391Ter ation
[0081] BRCA2 Mutation Frame Shift D c.4074del p.Phel358Le el ufsTerl6 BRCA2 Mutation Frame Shift D c.7530_7531del p.Tyr2511Se el rfsTer27 BRCA2 Mutation Frame Shift D c.6206del p.Leu2069Te el r BRCA2 Mutation Missense_Mut C.938OG p.Ser313Cys ation
[0082] BRCA2 Mutation Missense_Mut c.8471G>T p.Arg2824Ile ation
[0083] BRCA2 Copy Deletion - - number
[0084] alteration
[0085] FAT 3 Mutation Missense_Mut c.11669G>A p.Gly389OAs ation P
[0086] FAT 3 Mutation Nonsense_Mut c.10546G>T p.Glu3516Te ation r
[0087]
[0088] FAT 3 Mutation Missense_Mut C.9779OT p.Ala3260Va ation 1
[0089] FAT 3 Mutation Missense_Mut c.3085G>A p.VallO29M ation et FOXA1 Mutation In Frame Del c.793_864del p.Arg265_Ly s288del FOXA1 Mutation Frame Shift l c.765_766dup p.Asn256Arg ns fsTer66 FOXA1 Mutation Frame Shift D c.1196_1283del p.Pro399Leu el fsTerl2 FOXA1 Mutation Missense_Mut C.672OA p.Phe224Leu ation
[0090] FOXA1 Mutation Frame Shift D c.208_220del p.Asn70Glyf el sTer4 FOXA1 Mutation In Frame Del c.752_760del p.Gly251_Ph e254delinsV al ATRX Mutation Missense_Mut C.6457OT p.Arg2153C ation ys ATRX Mutation Missense_Mut C.5532OG p.Cysl844Tr ation P ZFHX3 Mutation Frame Shift l c.5774dup p.Glyl926Tr ns pfsTer3 ZFHX3 Mutation Missense_Mut c.1167G>T p.Gln389His ation
[0091] ZFHX3 Mutation Missense_Mut c.2195A>T p.Asn732Ile ation
[0092] ZFHX3 Mutation In Frame Del c.2330_2332del p.Val777del
[0093]
[0094] LRP1B Mutation Frame Shift D c.1893 del p.Ala632Leu el fsTer9 LRP1B Mutation Missense_Mut c.4241G>T p.Argl414Ile ation
[0095] LRP1B Mutation Missense_Mut c.5242T>A p.Tyrl748As ation n NRG1 Mutation Missense_Mut c.236G>T p.Arg79Leu ation
[0096] NRG1 Mutation Missense_Mut c.169A>T p.Arg57Trp ation
[0097] NRG1 Mutation Missense_Mut c.301T>A p.CyslOlSer ation
[0098] NRG1 Mutation Missense_Mut c.1847G>T p.Gly616Val ation
[0099] CDK12 Mutation Missense_Mut c.2455G>T p.Asp819Tyr ation
[0100] CDK12 Mutation Missense_Mut C.2864OG p.Pro955Arg ation
[0101] CDK12 Mutation Missense_Mut c.2080C>T p.Pro694Ser ation
[0102] CDK12 Mutation Frame Shift l c.330dup p.HislllThrf ns sTerl6 CDK12 Mutation Missense_Mut C.2678OA p.Thr893Lys ation
[0103] MMP1 Mutation Missense_Mut c.409G>A p.Alal37Thr ation
[0104] MMP1 High - - - expression
[0105]
[0106] FGFR3 Mutation Missense_Mut c.518G>A p.Argl73His ation
[0107] FGFR3 Mutation Missense_Mut c.2374G>A p.Asp792As ation n FGFR3 High - - - expression
[0108] CHDH Mutation Missense_Mut C.938OT p.Ala313Val ation
[0109] CHDH High - - - expression
[0110] DNAH8 Mutation Missense_Mut C.13468OT p.Arg4490C ation ys DNAH8 Mutation Missense_Mut C.5096OG p.Serl699Cy ation s DNAH8 Mutation Missense_Mut C.4609OT p.Argl537C ation ys DNAH8 Mutation Nonsense_Mut c.8656G>T p.Gly2886Te ation r DNAH8 Mutation Missense_Mut c.2123T>C p.Leu708Pro ation
[0111] DNAH8 High - - - expression
[0112] SLC45A3 Mutation Missense_Mut c.157A>G p.Met53Val ation
[0113] SLC45A3 High - - - expression
[0114] SLC4A4 Mutation Missense_Mut C.1725OA p.Phe575Leu ation
[0115]
[0116] SLC4A4 Mutation Missense_Mut c.2769G>A p.Met923Ile ation
[0117] SLC4A4 High - - - expression
[0118] EP HA 10 Mutation Missense_Mut c.2263G>A p.Ala755Thr ation
[0119] EP HA 10 High - - - expression
[0120] FGFRL1 High - - - expression
[0121] TBC1D4 Mutation Missense_Mut C.179OA p.Ala60Asp ation
[0122] TBC1D4 High - - - expression
[0123] TAF1L Mutation Missense_Mut c.857G>A p.Arg286His ation
[0124] GLI3 Mutation Missense_Mut c.3070T>C p.PhelO24Le ation u FBXO11 Mutation Missense_Mut c.149A>C p.Gln50Pro ation
[0125] EPHB2 Mutation Missense_Mut c.1571A>G p.Tyr524Cys ation
[0126] HDAC9 Mutation Frame Shift D c.2784del p.Tyr929Thr el fsTer3 ZNF536 Mutation Missense_Mut C.613OT p.Arg205Cys ation
[0127] CTNNB1 Mutation Missense_Mut c.94G>A p.Asp32Asn ation
[0128]
[0129] CHD6 Mutation Missense_Mut C.5149OA p.Prol717Th ation r PKD1 Mutation Missense_Mut C.107600T p.Ala3587Va ation 1 ZFHX4 Mutation Missense_Mut c.2153T>C p.Met718Thr ation
[0130] DMBT1 Mutation Missense_Mut c.5987A>G p.Asnl996Se ation r NBPF26 Mutation In Frame ins c.1147_1148ins p.Arg383deli AGT nsGlnCys RBMX Mutation Frame Shift l c.904_905dup p.Ser303Hisf ns sTerl37 RBMX Mutation Missense_Mut C.902OT p.Pro301Leu ation
[0131] GRIN1 Amplificat - - - ion and
[0132] High
[0133] expression
[0134] GLI4 Amplificat - - - ion and
[0135] High
[0136] expression
[0137] GMEB2 Amplificat - - - ion and
[0138] High
[0139] expression
[0140] ATM Mutation Missense_Mut c.5558A>T p.Aspl853V ation al
[0141] ATM Mutation Frame Shift D c.952_953del p.Leu318Ala el fsTer4
[0142]
[0143] 85 ATM Copy Deletion - - number
[0144] alteration
[0145] 86 PTEN Mutation Missense_Mut C.742OT p.Pro248Ser ation
[0146] 87 PTEN Mutation Missense_Mut c.587A>C p.Hisl96Pro ation
[0147] 88 PTEN Copy Deletion - - number
[0148] alteration
[0149] 89 FANCA Copy Deletion - - number
[0150] alteration
[0151] 90 CYC1 Amplificat - - - ion and
[0152] High
[0153] expression
[0154] 91 CDHR2 Amplificat - - - ion and
[0155] High
[0156] expression
[0157]
[0158] Development of prognostic gene panel:
[0159] In a further embodiment of the present disclosure, due to the molecular heterogeneity of prostate cancer (PCa), clinicians face substantial challenges in accurately distinguishing indolent disease from aggressive forms, often resulting in misinterpretation of disease severity — such as the undertreatment of high-risk patients. To address this, tissue specimens are stratified based on Gleason scores into low-grade (GS < 8; N = 46) and high-grade (GS > 8; N = 43) groups, and the gene expression profiles between these two categories are compared. A heatmap (FIG 4) illustratingdifferentially expressed genes between high-grade and low-grade PCa specimens reveals a distinct transcriptomic signature associated with tumor aggressiveness.
[0160] Genes significantly upregulated in high-grade PCa specimens are identified as potential poor prognostic biomarkers, given their elevated expression in more advanced stages of disease. Among these, CIP2A — a known oncogene that promotes tumor growth by inhibiting PP2A and stabilizing c-Myc — and FAM83A — a modulator of EGFR and PI3K / AKT signaling associated with therapeutic resistance and adverse outcomes in multiple cancer types, including PCa — are notably upregulated. Furthermore, upregulation of CD200, an immune checkpoint regulator, suggests a possible mechanism of immune evasion in aggressive tumors. LETR1 and CAMK2N1, both implicated in epithelial-mesenchymal transition (EMT) and metastasis, are also found to be elevated. Additional upregulated genes, such as DSPP, DMP1, and SPAG6, are known to be associated with enhanced tumor motility and invasive potential.
[0161] Conversely, several genes are significantly downregulated in high-grade PCa specimens, including EGR3, a transcription factor involved in apoptosis and cellular differentiation, and IST1, a regulator of membrane dynamics and cytokinesis. The downregulation of these genes suggests a loss of tumor-suppressive functions in aggressive disease states. Collectively, these findings underscore the utility of this gene set as putative poor prognostic signature genes in PCa, which may guide better therapeutic interventions.
[0162] In a further embodiment of the present disclosure, to enhance the robustness and translational relevance of the identified diagnostic and prognostic gene panels, a curated set of well-established genes reported across large-scale prostate cancer cohorts such as TCGA, SU2C, and MSKCC is incorporated for benchmarking and validation. These genes are consistently altered in multiple independent datasets and possess well-documented biological significance in prostate cancer initiation, progression, and subtype differentiation. For diagnostic utility, canonical alterations involving ERG,PTEN, IDH1, SPOP, and FOXA1 are included to capture hallmark genetic events and subtype-specific markers. In parallel, for prognostic assessment, genes such as MYC and AR — known to be amplified and upregulated in advanced or castration-resistant prostate cancer (CRPC) — are incorporated, along with BRCA1 / 2, which are implicated in homologous recombination repair deficiency and genomic instability. Additionally, CDK12 (biallelically inactivated in aggressive PCa subtypes with immune infiltration), RBI, and CHD1 (both frequently deleted and associated with poor clinical outcomes) are included due to their strong correlation with tumor aggressiveness and adverse prognosis. The finalized list of putative prognostic markers integrated into the prognostic gene panel is provided in Table 2.
[0163] Table 2: Prognostic gene panel
[0164] Sr No Genes Alteration type Alteration details
[0165] Differential exppression Up regulated in high grade PCa 1 CIP2A
[0166] specimens
[0167] Differential exppression Up regulated in high grade PCa 2 BAHCC1
[0168] specimens
[0169] Differential exppression Up regulated in high grade PCa 3 CD200
[0170] specimens
[0171] Differential expression Up regulated in high grade PCa 4 FAM83A
[0172] specimens
[0173] Up regulated in high grade PCa 5 LETR1 Differential exppression
[0174] specimens
[0175] Up regulated in high grade PCa 6 DMP1 Differential exppression
[0176] specimens
[0177] Up regulated in high grade PCa 7 CHRM2 Differential exppression
[0178] specimens
[0179]
[0180] Up regulated in high grade PCa 8 DSPP Differential exppression
[0181] specimens
[0182] Up regulated in high grade PCa 9 SPAG6 Differential exppression
[0183] specimens
[0184] Up regulated in high grade PCa 10 CAMK2N1 Differential exppression
[0185] specimens
[0186]
[0187] In yet another embodiment of the present disclosure, the inclusion of these well-known prostate cancer (PCa)-associated genes as a reference standard serves to establish a valuable benchmark for concordance analysis, thereby validating the biological and clinical relevance of the novel genes and mutations identified specifically within the Indian patient cohort. This strategic integration not only reinforces the scientific robustness of the proposed diagnostic and prognostic gene panels but also enhances their generalizability and potential for broader clinical application across diverse populations.
[0188] In a further embodiment of the present disclosure, the novelty lies in the integration of genomic and transcriptomic data from prostate cancer patients of Indian origin to develop a unique gene panel encompassing various somatic alterations. As no comprehensive omics data exist for this population, current diagnosis relies mainly on PSA levels and biopsy. Unlike these conventional methods, the proposed panel detects molecular alterations at multiple levels, enabling early diagnosis and effective risk stratification. Importantly, the panel includes novel alterations specific to Indian patients that have not been previously reported.
[0189] In a further embodiment of the present disclosure, the putative diagnostic panel derived from multi-omics data integration comprises genetic alterations exclusively identified in PCa tissue specimens, as well as early diagnostic somatic changes detected in PIN specimens. This facilitates the identification of molecular alterations prior toobservable histopathological changes. The panel, incorporating mutations, copy number alterations, and differentially expressed genes, enables prostate cancer detection through tissue biopsy, minimally invasive liquid biopsy, or urine-based assays. The gene panel is adaptable for use in qPCR, IHC, and NGS-based detection platforms. For liquid biopsy, detection from biological fluids such as blood, plasma, or urine is achieved by isolating cfDNA and CTCs, and identifying aberrations via ddPCR, qPCR, or NGS. This approach is particularly suitable for high-risk yet asymptomatic individuals and supports routine screening and early diagnosis, thereby improving patient compliance.
[0190] In a further embodiment of the present disclosure, the prognostic gene panel provides critical insights into tumor biology by distinguishing between indolent and aggressive forms of prostate cancer, thus enabling precise clinical decision-making. Unlike conventional methods that rely solely on histopathological grading, this panel incorporates molecular indicators of tumor progression and burden, allowing for a more nuanced assessment of patient risk. It is particularly valuable in guiding treatment strategies — such as identifying candidates for active surveillance versus those requiring aggressive therapy — by integrating molecular features with clinical parameters. Additionally, the ability to monitor these prognostic markers over time enhances patient management, particularly in cases where repeated tissue biopsies are not feasible.
[0191] By integrating diagnostic, prognostic, and early detection capabilities, the gene panel may provide a more comprehensive tool for prostate cancer management compared to single-marker tests or conventional diagnostic methods. This integrated approach may support more informed decision-making throughout the continuum of prostate cancer care, from initial screening to treatment selection and monitoring.
[0192] In a further embodiment of the present disclosure, the proposed gene panel also holds utility as a research tool for advancing the understanding of prostate cancer tumorbiology, which is currently under exploration. Several genes included in the panel are known to be actionable or serve as targets for existing or emerging therapeutic agents, thereby supporting the development of novel strategies for therapeutic intervention and precision medicine approaches in prostate cancer management.
[0193] The present invention is explained further in the following specific examples, which are only by way of illustration and are not to be construed as limiting the scope of the invention.
[0194] Examples
[0195] Example 1: Detection of Somatic Mutations
[0196] Genomic DNA isolated from prostate tissue samples or from FFPE specimens can be analyzed for somatic mutations in target genes such as KMT2C, BRCA2, ZFHX3, and CDK12. Selected exonic regions may be amplified using multiplex PCR or qPCR-based approaches, followed by mutation detection using allele-specific assays or sequencing methods (e.g., Sanger or targeted NGS). This approach enables identification of clinically relevant non-silent mutations for diagnostic and prognostic assessment.
[0197] Example 2: Copy Number Determination Using ddPCR
[0198] Copy number alterations in genes such as GRIN1, BRCA2 and / ’77'jVcan be quantified using droplet digital PCR (ddPCR). DNA samples are partitioned into thousands of droplets and amplified using gene-specific and reference assays. Absolute quantification allows detection of copy number gains or losses, supporting assessment of genomic alterations associated with disease progression and risk.
[0199] Example 3: Expression Profiling Using RT-qPCR
[0200] RNA extracted from prostate tissue samples can be used to evaluate expression levels of genes including CIP2A, FAM83A, CD200, CAMK2N1, and SPAG6. Reversetranscription followed by quantitative PCR (RT-qPCR) may be performed, with normalization to reference genes such as GAPDH. Relative expression analysis can help distinguish aggressive from indolent tumors and support prognostic classification.
[0201] Example 4: Liquid Biopsy Detection from Plasma ctDNA
[0202] Circulating tumor DNA (ctDNA) extracted from plasma samples can be analyzed for tumor-specific alterations in genes such as BRCA2, ATRX, CDK12 etc. Sensitive methods such as ddPCR or targeted sequencing can detect low-frequency variants. Serial monitoring of ctDNA levels may be used to track disease progression, treatment response, and residual disease in a minimally invasive manner.
[0203] Example 5: Urine-Based Early Detection
[0204] Nucleic acids extracted from first-void urine samples can be analyzed for alterations in selected panel genes including RBMX, ATM, FGFR3 etc. Detection may be performed using allele-specific PCR, ddPCR, or sequencing-based approaches. This non-invasive method has potential for early detection and differentiation of prostate cancer from benign conditions.
[0205] Example 6: NGS-Based Comprehensive Profiling
[0206] A targeted next-generation sequencing (NGS) panel comprising these diagnostic and prognostic genes identified through multi-omics analysis can be used for comprehensive molecular profiling. Libraries may be prepared using multiplex amplification and sequenced on platforms such as Illumina MiSeq (2x150 bp reads, average depth 500X). Bioinformatic analysis can identify somatic mutations and infer copy number alterations, which can be integrated with expression data from complementary assays. This combined approach enables simultaneous detection of multiple molecular alterations for diagnostic and prognostic applications.
[0207] Example 7: Protein Expression Analysis Using Immunohistochemistry (IHC)Protein expression of selected panel genes can be evaluated in prostate tissue sections using immunohistochemistry (IHC). Formalin-fixed paraffin-embedded (FFPE) tissues may be stained with specific antibodies targeting proteins encoded by genes such as CIP2A, FAM83A, and CAMK2N1. Staining intensity and distribution can be semi-quantitatively scored to assess overexpression or loss of protein expression. This approach enables correlation of molecular alterations with protein-level changes and supports prognostic stratification.
[0208] Example 8: Copy Number and Structural Alteration Detection Using Fluorescence In-Situ Hybridization (FISH)
[0209] Copy number alterations and structural variations in panel genes can be assessed using fluorescence in situ hybridization (FISH). Fluorescently labeled probes targeting genomic loci of interest, such as PTEN, BRCA2, and FANCA, may be hybridized to interphase nuclei in tissue sections. Signal enumeration allows detection of gene amplifications, deletions, or rearrangements. This method provides spatial confirmation of copy number changes identified through sequencing or PCR-based approaches.
[0210] Example 9: Spatial Gene Expression Analysis Using RNA In Situ Hybridization (RNA-ISH)
[0211] Spatial expression of selected genes can be analyzed using RNA in situ hybridization (RNA-ISH) in prostate tissue sections. Target-specific probes can be designed for genes such as CD200, CIP2A, and FAM83A. Hybridization signals can be visualized as punctate staining within cells, enabling localization and quantification of transcript levels. This approach allows assessment of gene expression heterogeneity within tumor and surrounding microenvironment.
[0212] Example 10: Circulating Protein Detection Using ELISAProtein products of selected panel genes or associated biomarkers can be measured in blood samples using enzyme-linked immunosorbent assay (ELISA). Serum or plasma samples may be analyzed using antibodies specific to proteins encoded by genes showing altered expression, such as SPAG6 or CD200. Quantitative measurement of circulating protein levels can complement genomic and transcriptomic findings and may support non-invasive monitoring of disease status.
[0213] A number of implementations have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the disclosure.
[0214] Numerous advantages of the present disclosure may be apparent from the discussion above.
[0215] The present invention provides a comprehensive multi-omics gene panel that integrates somatic mutations, copy number alterations, and gene expression changes within a single structured platform, thereby offering superior molecular characterization compared to single-marker assays. By incorporating early driver mutations identified in PIN lesions, the panel enables detection of prostate cancer at pre-malignant or early stages, facilitating timely intervention. Developed using Indian patient cohorts, the panel captures population-specific genomic alterations, ensuring improved clinical relevance and accuracy for the target demographic.
[0216] The present invention reliably differentiates malignant prostate cancer from benign prostatic hyperplasia, overcoming limitations of PSA-based testing and reducing unnecessary biopsies. The inclusion of prognostic markers enables precise stratification between indolent and aggressive disease, supporting appropriate treatment selection and minimizing both overtreatment and undertreatment. The panel is optimized for minimally invasive liquid biopsy applications using blood, plasma, or urine samples, allowing routine screening and longitudinal monitoring.The present invention’s cmpatibility with multiple detection platforms such as qPCR, ddPCR, NGS, microarray, and IHC ensures broad implementation across varied laboratory settings. Additionally, the identification of actionable alterations, including FGFR3, BRCA1 / 2, and CDK12, supports precision medicine approaches. By enabling early diagnosis and optimized therapy selection, the present invention provides reduces overall healthcare costs. The flexible and scalable design further enhances accessibility in resource- limited settings, addressing critical disparities in advanced molecular diagnostics.
[0217] Therefore, the present invention provides a technically robust and clinically transformative multi-omics gene panel that integrates mutation, copy number, and transcriptomic markers into a unified molecular framework for prostate cancer characterization. By combining early detection capability, accurate differential diagnosis, reliable prognostic stratification, and identification of actionable therapeutic targets within a platform-flexible and minimally invasive format, the invention advances precision oncology beyond conventional single-marker approaches. Its population-specific design, scalability, and cost-effectiveness further enhance its translational value, positioning the panel as a comprehensive and accessible solution for improving prostate cancer management across diverse healthcare settings.
[0218] While specific language has been used to describe the invention, any limitations arising on account of the same are not intended. As would be apparent to a person skilled in the art, various working modifications may be made to the method in order to implement the inventive concept as taught herein.
[0219] The figures and the foregoing description give examples of embodiments. Those skilled in the art will appreciate that one or more of the described elements may well be combined into a single functional element. Alternatively, certain elements may be split into multiple functional elements.Elements from one embodiment may be added to another embodiment. For example, order of processes described herein may be changed and are not limited to the manner described herein. Moreover, the actions of any flow diagram need not be implemented in the order shown; nor do all of the acts need to be necessarily performed. Also, those acts that are not dependent on other acts may be performed in parallel with the other acts. The scope of embodiments is by no means limited by these specific examples.
Claims
WE CLAIM:
1. A multi-omics nucleic acid probe panel comprising:a combination of at least one of synthetic oligonucleotides, primers, and hybridization probes designed to hybridize at least one of genomic DNA sequences and complementary DNA (cDNA) sequences corresponding to the following genes:(a) KMT2C, BRCA2, ATRX, ZFHX3, FAT3, FOXA1, LRP1B, NRG1, and CDK12-,(b) GRIN1, GMEB2, ATM, PTEN, FANCA, CYC1, and CDHR2, (c) HDAC9, MMP1, FGFR3, SLC4A4, DNAH8, and SLC45A3' and (d) CIP2A, FAM83A, CD200, LETR1, CAMK2N1, DSPP, DMP1, SPAG6, BAHCC1, and CHRM2,'wherein at least one of the synthetic oligonucleotides, primers, and hybridization probes are configured to detect at least one of somatic non- silent mutations, genomic copy number alterations, and differential transcript expression levels.
2. The multi-omics nucleic acid probe panel as claimed in claim 1, further comprising a subset of at least one of the synthetic oligonucleotides, primers, and hybridization probes configured to detect early-stage driver mutations in RBMX, DMBT1, CHD6, and ZFHX4.
3. The multi-omics nucleic acid probe panel as claimed in claim 1, wherein at least one of the synthetic oligonucleotides, primers, and hybridization probescorresponding to KMT2C, BRCA2, ATRX, and ZFHX3 are designed to hybridize to exonic regions associated with non-silent somatic mutations.
4. The multi-omics nucleic acid probe panel as claimed in claim 1, wherein at least one of the synthetic oligonucleotides, primers, and hybridization probes corresponding to GRIN1, GMEB2, CYC1, and CDHR2 are configured to quantify genomic amplification events.
5. The multi-omics nucleic acid probe panel as claimed in claim 1, wherein at least one of the synthetic oligonucleotides, primers, and hybridization probes corresponding to PTEN, ATM, and FANCA are configured to quantify genomic deletion events.
6. The multi-omics nucleic acid probe panel as claimed in claim 1, wherein at least one of the synthetic oligonucleotides, primers, and hybridization probes corresponding to CIP2A, FAM83A, CD200, LETR1, CAMK2N1, BAHCC1, and CHRM2 are configured to quantify transcript abundance through reverse transcription and amplification.
7. The multi-omics nucleic acid probe panel as claimed in claim 1, further comprising at least one of synthetic oligonucleotides, primers, and hybridization probes specific for at least one reference gene selected from ERG, IDH1, SPOP, MYC, AR, RBI, and CHD1.
8. The multi-omics nucleic acid probe panel as claimed in claim 1, wherein the synthetic oligonucleotides have a length between 15 and 30 nucleotides and a melting temperature (Tm) between 55 °C and 65 °C.
9. The multi-omics nucleic acid probe panel as claimed in claim 1, wherein the hybridization probes comprise fluorescent labels selected from at least one of FAM, VIC, NED, ROX, Cy3, Cy5, and Texas Red.
10. A kit for a molecular profiling and risk stratification of prostate cancer, comprising:(a) the multi-omics nucleic acid probe panel as claimed in claim 1 ;(b) reagents suitable for nucleic acid extraction from a biological sample; (c) reagents for at least one of nucleic acid amplification and hybridization; and(d) at least one of a detectable label and a marker.
11. The kit as claimed in claim 10, wherein the reagents suitable for nucleic acid extraction is selected from a group comprising of silica-based spin columns, magnetic beads, chaotropic salts, and Proteinase K configured for an isolation of at least one of DNA and RNA from at least one of fresh tissue and formalin-fixed paraffin-embedded (FFPE) tissue.
12. The kit as claimed in claim 10, wherein the reagents for at least one of nucleic acid amplification and hybridization is selected from the group comprising of a thermostable DNA polymerase, a reverse transcriptase, deoxynucleotide triphosphates (dNTPs), buffer solutions, and ligases configured for one of multiplex PCR and next-generation sequencing (NGS) library preparation.
13. The kit as claimed in claim 10, wherein at least one of the detectable label and the marker is selected from the group comprising of a fluorophore, a biotinyl moiety, a chemiluminescent agent, an enzymatic conjugate, and a radioisotope.
14. The kit as claimed in claim 10, wherein the biological sample is selected from at least one of fresh tissue, formalin-fixed paraffin-embedded (FFPE) tissue, blood, plasma, serum, urine, circulating tumor cells (CTCs), and cell-free DNA (cfDNA).
15. The kit as claimed in claim 10, wherein the kit is configured to use with at least one of a next-generation sequencing (NGS) platform, a quantitative polymerase chain reaction (qPCR) platform, and a digital droplet PCR (ddPCR) platform.
16. The kit as claimed in claim 10, wherein the kit comprises reagents packaged in separate vessels optimized for storage at temperatures between -20 °C and 25 °C.
